Copyright
©2013 Baishideng Publishing Group Co.
World J Gastroenterol. Dec 28, 2013; 19(48): 9156-9173
Published online Dec 28, 2013. doi: 10.3748/wjg.v19.i48.9156
Published online Dec 28, 2013. doi: 10.3748/wjg.v19.i48.9156
Ref. | Study population | Transplant type/analysis of recipients, donors or both | Findings |
Jun et al[98] | 568 Korean | Kidney and liver recipients (n = 506), and liver donors (n = 62) | No difference in incidence of organ rejection between different genotypes |
Chen et al[103] | 120 Chinese | Kidney recipients | Patients that received genotype-guided initial tacrolimus dosing vs standard protocol dose were more likely to achieve target drug levelsNo influence on incidence of adverse effects between CYP3A5 expressers and non-expressers |
Jacobson et al[105] | 945 (different ethnicities) | Kidney recipients | Every increase in tacrolimus blood trough level of 1 ng/mL increased the risk of early tacrolimus nephrotoxicity by 22%Polymorphism was not associated with an increased or decreased risk of tacrolimus-related nephrotoxicity |
Kuypers et al[106] | 273 White,3 Hispanic,24 North African,2 African,2 Asian | Kidney recipients | Delayed graft function was associated with higher initial mean tacrolimus blood trough levels and lower tacrolimus daily dose requirements, especially in CYP3A5 non-expressersCYP3A5 expressers may be at lower risk of new-onset diabetes after transplant (NODAT) due to diminished exposure to potentially toxic tacrolimus levels |
Kuypers et al[104] | 273 White,3 Hispanic,24 North African,2 African,2 Asian | Kidney recipients | Patients expressing the CYP3A5*1 allele and a functional CYP3A5 enzyme may be predisposed to developing calcineurin-inhibitor-associated nephrotoxicity (CNIT) following transplantation due to greater daily tacrolimus dose requirementsThis was observed especially in patients continuing corticosteroid therapy The incidence of delayed graft function and post-transplant diabetes mellitus was not different between CYP3A5 expressers and non-expressers |
Chen et al[107] | 319 Hispanic | Kidney recipients | SNPs in the cytoplasmic NFATc4 gene may confer a certain protection or also predisposition for NODAT. Patients carrying the T allele and the T-T-T-T-G haplotype showed a trend of protection from NODAT while patients with the C-C-C-G-G haplotype were associated with an increased risk of NODATThe use of sirolimus and tacrolimus and advanced age were also possibly correlated in development of NODAT |
Cho et al[84] | 70 Korean | Kidney recipients | Higher drug-related toxicity in patients with the CYP3A5*1 allele than in those with the CYP3A5*3 SNPNo difference in graft survival between the two genotypes |
Barrera-Pulido et al[94] | 53 Spanish | Liver recipients and donors | Patients with CYP3A5*3/*3 allele receiving livers with an ABCB1 SNP had lower frequency of renal dysfunction, same rejection rate and higher diabetes rate |
Shi et al[66] | 216 Chinese | Liver recipients | Patients with the CPY3A5*3 allele had greater risk of early renal injury than the patients with the *1 allele |
- Citation: Provenzani A, Santeusanio A, Mathis E, Notarbartolo M, Labbozzetta M, Poma P, Provenzani A, Polidori C, Vizzini G, Polidori P, D’Alessandro N. Pharmacogenetic considerations for optimizing tacrolimus dosing in liver and kidney transplant patients. World J Gastroenterol 2013; 19(48): 9156-9173
- URL: https://www.wjgnet.com/1007-9327/full/v19/i48/9156.htm
- DOI: https://dx.doi.org/10.3748/wjg.v19.i48.9156